Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transcriptome profiling Clear all
Terminated Phase 1 Interventional

Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

NCT00747305
View directory record Official record
Conditions
Kidney Cancer
Interventions
sunitinib malate, gene expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Harry Drabkin
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

NCT00389805
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, pemetrexed disodium, gene expression analysis, mutation analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, immunohistochemistry staining method
Drug · Genetic · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 22, 2026, 10:16 PM EDT
Not listed No phase listed Observational

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

NCT03521245
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
RNA sequencing, Transcriptome analysis, Trastuzumab, Chemotherapy
Other · Drug
Lead sponsor
OmicsWay Corp.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Timeline
2017 – 2022
U.S. locations
1
States / cities
Walnut, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 1 Interventional

Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

NCT00641030
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
clofarabine, melphalan, gene expression analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 10:16 PM EDT
Terminated No phase listed Observational

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00899197
View directory record Official record
Conditions
Breast Cancer
Interventions
tamoxifen citrate, gene expression analysis, protein expression analysis, immunoenzyme technique, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 22, 2026, 10:16 PM EDT
Terminated Not applicable Interventional Results available

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

NCT01280643
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, irinotecan hydrochloride, bevacizumab, cetuximab, capecitabine, mutation analysis, gene expression analysis, laboratory biomarker analysis, immunohistochemistry staining method, nucleic acid sequencing, protein expression analysis, polymerase chain reaction, DNA analysis
Drug · Biological · Genetic + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 22, 2026, 10:16 PM EDT
Not listed No phase listed Observational

Gene Expression Profiling in Subjects With Postoperative Atrial Fibrillation After Cardiac Surgery (GENEXPRO Surg)

NCT00833313
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Atrial biopsy
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 99 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 22, 2026, 10:16 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia

NCT00363779
View directory record Official record
Conditions
Large Granular Lymphocytic Leukemia, LGL Leukemia
Interventions
Cyclosporine, Gene expression analysis, Microarray analysis, Laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 1 Interventional

A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

NCT00353158
View directory record Official record
Conditions
Healthy Volunteers, Fungal Infections, Bacterial Infections
Interventions
Doxycycline, Voriconazole
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
8 Years to 100 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 10:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

NCT03326076
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
Diagnostic Test · Other
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
72
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 22, 2026, 10:16 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing

NCT01833195
View directory record Official record
Conditions
Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
15 Years and older
Enrollment
2,444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
36
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 10:16 PM EDT
Not listed No phase listed Observational

Molecular Biomarkers in Renal Transplantation Via TruGraf® Test

NCT04398498
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Diagnostic Test: TruGraf® Testing
Diagnostic Test
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 22, 2026, 10:16 PM EDT
Completed No phase listed Observational

Study of Specimens From Young Patients With Neuroblastoma

NCT00958659
View directory record Official record
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4S Neuroblastoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 22, 2026, 10:16 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

NCT00233948
View directory record Official record
Conditions
Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
nelfinavir mesylate, biopsy, laboratory biomarker analysis, pharmacological study, gene expression analysis, western blotting, reverse transcriptase-polymerase chain reaction, immunoenzyme technique
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 22, 2026, 10:16 PM EDT
Not listed No phase listed Observational

Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests

NCT00258869
View directory record Official record
Conditions
Sepsis, Septicemia, Sepsis Syndrome, Shock, Septic, Community Acquired Pneumonia
Interventions
Not listed
Lead sponsor
National Center for Genome Resources
Other
Eligibility
6 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 22, 2026, 10:16 PM EDT
Completed No phase listed Observational

Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

NCT00897663
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gene expression analysis, microarray analysis, protein expression analysis, diagnostic laboratory biomarker analysis, immunohistochemistry staining method
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Sioux City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 22, 2026, 10:16 PM EDT
Not listed Phase 2 Interventional

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

NCT00717587
View directory record Official record
Conditions
Kidney Cancer
Interventions
motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 22, 2026, 10:16 PM EDT
Completed No phase listed Observational

Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma

NCT01474564
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
5
States / cities
Commack, New York • Harrison, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

NCT00509093
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate, gene expression analysis, mutation analysis, polymerase chain reaction, flow cytometry, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Buffalo, New York • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 22, 2026, 10:16 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment

NCT00538291
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, capecitabine, gene expression analysis, microarray analysis, polymorphism analysis, reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method
Biological · Drug · Genetic + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 22, 2026, 10:16 PM EDT
Terminated Phase 2 Interventional Results available

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

NCT00665457
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, capecitabine, celecoxib, cyclophosphamide, docetaxel, doxorubicin hydrochloride, gene expression analysis, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, imaging biomarker analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacogenomic studies, dynamic contrast-enhanced magnetic resonance imaging, needle biopsy, neoadjuvant therapy, radiomammography, ultrasound imaging
Biological · Drug · Genetic + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 22, 2026, 10:16 PM EDT
Not listed No phase listed Observational

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

NCT00900224
View directory record Official record
Conditions
Leukemia
Interventions
DNA analysis, DNA methylation analysis, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
77
States / cities
Mountain View, California • Lewes, Delaware • Newark, Delaware + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Not applicable Interventional

Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria

NCT02814630
View directory record Official record
Conditions
Chronic Idiopathic Urticaria
Interventions
Xolair
Biological
Lead sponsor
Asthma Inc Clinical Research Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 22, 2026, 10:16 PM EDT
Completed Phase 1 Interventional

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

NCT00379509
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, TdT-mediated dUTP nick end labeling assay, gene expression analysis, microarray analysis, immunohistochemistry staining method, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 22, 2026, 10:16 PM EDT